Mometasone and Markers of Airway Inflammation
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00711165 |
Recruitment Status :
Completed
First Posted : July 8, 2008
Last Update Posted : July 8, 2008
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Asthma | Drug: Placebo Drug: Mometasone Furoate | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 12 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Treatment |
Official Title: | The Effects of Mometasone on Markers of Airway Inflammation |
Study Start Date : | August 2005 |
Actual Primary Completion Date : | April 2006 |
Actual Study Completion Date : | August 2006 |

Arm | Intervention/treatment |
---|---|
Placebo Comparator: Placebo
Placebo, 2 puffs, bid
|
Drug: Placebo
2 puffs, qd |
Experimental: Memetasone
Mometasone
|
Drug: Mometasone Furoate
400 mcg, qd for 8 weeks
Other Name: asmanex |
- Exhaled Nitric Oxide [ Time Frame: 8 weeks ]
- Airway Reactivity [ Time Frame: 8 weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 19 Years to 50 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Asthma
- non-smoker
- FEV1 of at least 60% predicted
Exclusion Criteria:
- Pregnancy or lactation
- Corticosteroid use in past 30 days

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00711165
United States, Nebraska | |
Creighton University Medical Center | |
Omaha, Nebraska, United States, 68131 |
Principal Investigator: | Thomas B Casale, MD | Creighton University |
Responsible Party: | Thomas B. Casale, MD, Creighton University |
ClinicalTrials.gov Identifier: | NCT00711165 |
Other Study ID Numbers: |
Mometasone TBC |
First Posted: | July 8, 2008 Key Record Dates |
Last Update Posted: | July 8, 2008 |
Last Verified: | July 2008 |
Asthma Nitric Oxide Exhaled Breath Condensate Methacholine Challenge |
Inflammation Pathologic Processes Mometasone Furoate |
Anti-Inflammatory Agents Dermatologic Agents Anti-Allergic Agents |